Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.

Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy.

A series of novel 2-arylbenzoxazoles that upregulate the production of utrophin in murine H2K cells, as assessed using a luciferase reporter linked assay, have been identified. This compound class appears to hold considerable promise as a potential treatment for Duchenne muscular dystrophy. Followin...

Bibliografski detalji
Glavni autori:	Chancellor, DR, Davies, K, De Moor, O, Dorgan, C, Johnson, P, Lambert, A, Lawrence, D, Lecci, C, Maillol, C, Middleton, P, Nugent, G, Poignant, S, Potter, A, Price, P, Pye, R, Storer, R, Tinsley, J, van Well, R, Vickers, R, Vile, J, Wilkes, F, Wilson, F, Wren, S, Wynne, G
Format:	Journal article
Jezik:	English
Izdano:	2011

Slični predmeti

Utrophin upregulation in Duchenne muscular dystrophy.
od: Hirst, R, i dr.
Izdano: (2005)

Identification of new chemical compounds with upregulate utrophin for the therapy of Duchenne muscular dystrophy
od: Fairclough, R, i dr.
Izdano: (2012)

Utrophin in the therapy of Duchenne Muscular Dystrophy
od: Potter, A, i dr.
Izdano: (2006)

Evaluation of novel compounds for upregulation of utrophin in animal models of Duchenne muscular dystrophy therapy
od: Fairclough, R, i dr.
Izdano: (2008)

Utrophin in therapy of Duchenne muscular distrophy
od: Fisher, R
Izdano: (2001)

Utrophin upregulation and microRNAs - two avenues of Duchenne muscular dystrophy therapy research
od: Bareja, A
Izdano: (2011)

Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
od: Tinsley, J, i dr.
Izdano: (2011)

Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers
od: Tinsley, J, i dr.
Izdano: (2015)

Utrophin luciferase knock-in mouse model for in vivo assessment of drug efficacy in preclinical trials for utrophin upregulation
od: Fairclough, R, i dr.
Izdano: (2010)

The role of utrophin in the potential therapy of Duchenne muscular dystrophy.
od: Perkins, K, i dr.
Izdano: (2002)

New orally available compounds which modulate utrophin expression for the therapy of Duchenne muscular dystrophy (DMD)
od: Fairclough, R, i dr.
Izdano: (2014)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
od: Guiraud, S, i dr.
Izdano: (2019)

Future clinical and biomarker development for SMTC1100, the first utrophin modulator to enter clinical trials for Duchenne Muscular Dystrophy (DMD)
od: Tinsley, J, i dr.
Izdano: (2013)

Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in Duchenne and Becker muscular dystrophy muscle biopsies
od: Janghra, N, i dr.
Izdano: (2016)

Utrophin upregulation in DMD therapy: current status and new tools for the future
od: Fairclough, R, i dr.
Izdano: (2011)

Expression of different isoforms of utrophin in human muscle; potentials for therapy of Duchenne muscular dystrophy
od: Sewry, C, i dr.
Izdano: (2004)

Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy.
od: Griffin, J, i dr.
Izdano: (2002)

Mechanism of action studies of the utrophin modulator ezutromid for the treatment of Duchenne muscular dystrophy
od: Wilkinson, I
Izdano: (2019)

Prevention of the dystrophic phenotype in dystrophin/utrophin-deficient muscle following adenovirus-mediated transfer of a utrophin minigene.
od: Wakefield, P, i dr.
Izdano: (2000)

Towards the elucidation of the mechanism of action of small molecule upregulators of utrophin using chemical proteomics
od: Vuorinen, A
Izdano: (2017)

Analysis of the transcriptional control of utrophin promoters as a therapeutic strategy for Duchenne muscular dystrophy (DMD).
od: Perkins, K, i dr.
Izdano: (2000)

Non-toxic ubiquitous overexpression of utrophin in the mdx mouse.
od: Fisher, R, i dr.
Izdano: (2000)

Second-generation compound for the modulation of utrophin in the therapy of DMD
od: Guiraud, S, i dr.
Izdano: (2015)

Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy
od: Perkins, K, i dr.
Izdano: (2018)

Non-toxic ubiquitous over-expression of utrophin in the mdx mouse.
od: Fisher, R, i dr.
Izdano: (2001)

The utrophin and dystrophin genes share similarities in genomic structure.
od: Pearce, M, i dr.
Izdano: (1993)

The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy.
od: Perkins, K, i dr.
Izdano: (2001)

A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.
od: Sewry, C, i dr.
Izdano: (2005)

Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system.
od: Squire, S, i dr.
Izdano: (2002)

Up-regulation of utrophin alleviates the dystrophic phenotype in the mdx mouse heart
od: Sang, E, i dr.
Izdano: (2000)

The artificial zinc finger coding gene 'Jazz' binds the utrophin promoter and activates transcription.
od: Corbi, N, i dr.
Izdano: (2000)

Confirmation by immunogold labeling that utrophin is localised to the normal position of dystrophin in dystrophin-negative transgenic mouse muscle
od: Cullen, M, i dr.
Izdano: (2001)

Regulation of utrophin in transgenic mice (multiple letters)
od: Davies, K, i dr.
Izdano: (2005)

From diagnosis to therapy in Duchenne muscular dystrophy
od: Babbs, A, i dr.
Izdano: (2020)

Regulation of utrophin in transgenic mice.
od: Davies, K
Izdano: (2005)

Understanding the endothelial function of utrophin.
od: Ehmsen, J, i dr.
Izdano: (2002)

Progress in therapy for Duchenne muscular dystrophy.
od: Fairclough, R, i dr.
Izdano: (2011)

Progress in therapy for Duchenne muscular dystrophy
od: Fairclough, R, i dr.
Izdano: (2011)

Molecular genetics of Duchenne muscular dystrophy.
od: Kunkel, L, i dr.
Izdano: (1986)

A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin.
od: Cole, M, i dr.
Izdano: (2002)